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Abstract. Because of high occurrence of side effects of conventional anticancer drugs, new 
therapies have been widely studied, such as the use of non-usual molecules and the association 
with nanomaterials. In this context, sildenafil is a molecule that has been lately considered as a 
co-adjuvant in cancer therapy because it inhibits an enzyme with a potential role in tumor 
progression, phosphodiesterase-5. Taking into account the combination of nanoparticles and 
sildenafil, we produced systems based on mesoporous silica nanoparticles, Pluronic F-127 and 
sildenafil as the main therapy for prostate cancer.  
1.  Introduction  
A major problem in cancer treatments is the high incidence of side effects intrinsic to anticancer drugs, 
which end up affecting the patients' lives and the therapies themselves. In an attempt to overcome this 
issue, the association of these drugs with non-usual molecules that act through different mechanisms 
as well as the association with nanomaterials are promising alternatives. In this way, sildenafil (SIL) is 
a molecule that inhibits an enzyme which expression is increased in many carcinomas, 
phosphodiesterase-5 (PDE-5) [1]. Moreover, it activates nitric oxide expression and apoptosis [2,3]. 
Among nanomaterials, mesoporous silica nanoparticles (MSNs) are good candidates to be used as 
drug carriers once they are safe and biocompatible [4]. They have high superficial area and great pore 
volume, very appropriate to carry bioactives [4]. They provide a sustained release of the drug, 
preventing it of premature degradation and increasing the effectiveness of drug delivery [4,5].  
Another strategy to ensure a better drug distribution is the association with materials that can 
provide prolonged release [6]. In this perspective, Pluronic F-127 (PF-127) is a FDA-approved 
biocompatible block copolymer that has a transition sol-gel temperature near room temperature [7]. 
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That is, it is liquid at low temperatures (e.g. refrigerator temperatures) and it gelates at room 
temperature, which makes it very suitable to reach in situ gelation [6], applying the liquid formulation 
inside the patient body for it to form a hydrogel in there.  
In order to obtain preliminary results about the antitumor potential of the association MSNs + SIL 
+ PF-127, the effect of SIL on prostate tumor cells and the role of the nanoparticles in this process, we 
developed three systems containing these components and tested them in rats with chemically induced 
prostate cancer. The MSNs were used as nanocarriers for SIL, to reach a sustained release of the drug 
and PF-127 was used as the matrix of the hydrogel, to achieve in situ gelation to reach a long-term 
release of the components.  
 
2.  Methods 
Synthesis and characterization of mesoporous silica nanoparticles (MSNs)  
The MSNs were synthesized through on a sol-gel method based on the methods of Stöber [8] [9] and 
Bein [9] [10] following the protocol developed by Paula et al. (2012) [10] [8]. This approach allow to 
synthesize spherical and monodisperse nanoparticles with high colloidal stability in aqueous medium. 
So, to synthesize the MSNs, 0.75 g of cetyltrimethylammonium bromide (CTAB) were added to a 
0.050 mol L
-1
 ammonium hydroxide solution of pH 11. Then, 3.2 mL of absolute ethanol were added 
and after 15 minutes under magnetic stirring, 2.5 mL of tetraethyl orthosilicate (TEOS) were added. 
The reaction was maintained under reflux at 60C for two hours. A centrifugation step was carried out 
to separate the products (60 minutes at 18,400 rcf). To extract the CTAB, the products were 
resuspended in 90 mL of absolute ethanol and 10 mL of hydrochloric acid were added (1:9 
HCL:Ethanol volume ratio), sonicating the mixture for 10 minutes. Finally, to obtain ethanolic 
suspensions of the nanoparticles, the mixture was centrifuged (60 minutes at 18,400 rcf) following two 
washing steps with absolute ethanol and resuspended in absolute ethanol.  
Transmission electron microscopy (TEM) in the bright field mode was used to analyze size 
distribution and morphology of MSNs (TEM-BF, Zeiss Libra 120, operating at 80 kV). Surface area, 
pore volume and pore diameter were obtained through nitrogen-sorption assays (Accelerated Surface 
Area and Porosimetry System ASAP 2020 micromeritics) using BET (Brunauer-Emmet-Teller) to 
calculate surface area and BJH (Barret-Hoyner-Halenda) to calculate pore diameter, both using N2 
adsorption branch. The pore volume was calculated from the single-point value adsorbed at P/P0 = 
~0.94.   
 
Synthesis and characterization of hybrid systems 
To evaluate the antitumor potential of the hybrid systems, the effect of SIL in tumor cells and the role 
of MSNs in the association, we developed three systems. The only difference between them was the 
presence and concentration of the MSNs (Table 1). The systems were produced by adding SIL to the 
PF-127 solution in an ice bath under magnetic stirring, then adding the nanoparticles lastly to avoid 
aggregation. The mixture was kept under magnetic stirring at 4C overnight. All systems were 
produced in physiological saline solution (0.9% w/v NaCl) to keep the same osmotic pressure than the 
animals’ cells.  
The concentration of SIL was calculated based on Das et al. (2010) [1] [2] to reach 5 mg of drug 
per kilogram of animal body weight, considering a dose application of 0.3 mL and an animal body 
weight of 150 g (average). The PF-127 concentration was chosen according to the desired range of 
gelation temperature (Tgel): the optimum Tgel would allow easy manipulation of the systems, avoiding 
gelation inside the and quickly gelation of the systems after applied intraperitoneally in the animals, 
avoiding diffusion to unwanted locations and premature release. So, the systems were characterized 
regarding their Tgel by adding 5 mL of the liquid mixture in a beacker in an ice bath with a 
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thermometer. The mixture was heated in a constant rate and the temperature in which the bar stopped 
moving was considered the gelation temperature.  
To obtain information on the potential for prolonged release of the systems, the release profile was 
studied in vitro through a membraneless dissolution method. To do so, 0.5 mL of ht hybrid systems 
were added to a weighed vial and incubated at 35C (which is the body temperature of mice used in 
the in vivo assays), using a dry bath, to reach thermal equilibrium. So, the vials were weighed and 0.5 
mL of the release medium (NaCl 0.9% w/v) were put carefully in order to avoid mixture. At pre-
determined intervals, the release medium was removed, the vial was weighed and a new release 
medium was put to avoid saturation. The dissolution rate was calculated in terms of weight loss 
against time.  
 
In vivo model 
The in vivo study was accomplished using seventeen 7-week-old male Fischer 344 rats, obtained from 
the Multidisciplinary Center for Biological Investigation (CEMIB) at University of Campinas 
(UNICAMP). The prostate cancer induction followed a new protocol based on Fávaro et al. (2014) [11 
- 11] and was performed in 13 animals. This new approach allows the animals to be ready for 
treatment in approximately four months. The animals received a daily subcutaneous injection of 100 
mg kg
-1
 testosterone cypionate diluted in 0.5 mL of peanut oil for three days. Then, the animals were 
anesthetized with 5 mg kg
-1
 of 2% xylazine hydrochloride and 60 mg kg
-1
 of 10% ketamyne 
hydrochloride in order to perform 0.5 cm suprapubic incision and inoculation of 0.2 mL of 15 mg kg
-1
 
of n-methyl-n-nitrosourea (MNU) dissolved in 0.3 mL of 1 M sodium citrate (pH 6.0) and 25% PF-
127, which allows in situ gelation of the solution. After one week, the animals received subcutaneous 
injections of 5 mg kg
-1 
testosterone cyprionate diluted in 5 mL of peanut oil on alternate days for 120 
days.  
Of the total number of animals, 4 animals comprised the healthy control group (Control, n=4, 
received no cancer induction) and 4 comprised the cancer group (Cancer, n=4, received no treatment), 
both groups received physiological saline (NaCl 0.9% w/v) for treatment. The rest of the animals were 
divided in 3 groups (n=3): Group S1 was treated with S1 system, Group S2 was treated with S2 
system and Group S3 was treated with S3 system. The treatment consisted of a weekly-dose of 
intraperitoneal inoculation of 0.3 mL of the respective treatment for 30 days. To prevent gelation 
inside the needles, the systems were kept in ice bath before each application. The animals received 
water and the same solid diet ad libitum (Nuvilab) and were allocadted in single solid-bottom boxes 
lined with wood shavings in a room with controlled light and temperature (12 hours light and 12 hours 
dark, 20-25C). The experimental protocol followed ethical principles in animal research. After 
treatment, the animals were euthanized and the occurrence of macroscopic changes were observed.  
  
3.  Results and Discussion 
 
Synthesis and characterization of MSNs  
It is possible to see through TEM images (Fig. 1a) that MSNs have spherical morphology and size 
distribution from 45 to 75 nm. Nitrogen-sorption experiments using BET and BJH methods revealed 
that the superficial area was 970 cm
2
 g
-1
 and the pore volume was 1.6 cm
3
 g
-1
, with an average pore 
diameter of 4.8 nm. The nitrogen-sorption isotherm (Fig. 1b) shows an adsorption pattern that 
resembles a type IV isotherm (IUPAC) with a subtle stepwise behavior around 0.4 P/P0, which is 
characteristic of well-ordered mesoporous materials [12].  
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Figure 1. a) TEM images of MSNs with size distribution histogram (measuring at least 100 
nanoparticles) b) Nitrogen sorption isotherm of MSNs 
 
Synthesis and characterization of hybrid systems 
The hybrid systems were characterized regarding their Tgel (Table 1). All systems have a Tgel that fits 
the temperature range preferred, which allows easy manipulation of them during dose applications and 
a rapid gelation inside the animal body (which temperature is around 35C).  
  
Table 1. Description of the hybrid systems. 
System Components and final concentration Gelation temperature 
(Tgel, C) 
S1 
PF-127 (18%) 
SIL (4.16 mg mL
-1
) 
21.0 ± 0.5 
 
S2 
PF-127 (18%) 
SIL (4.16 mg mL
-1
) 
MSNs (1.0 mg mL
-1
) 
 
20.0 ± 0.5 
 
S3 
PF-127 (18%) 
SIL (4.16 mg mL
-1
) 
MSNs (5.0 mg mL
-1
) 
 
19.0 ± 0.5 
 
 
 The potential for prolonged release was confirmed during the in vitro dissolution experiment (Fig. 
2). Considering the concentration gradient induced by cells permanently on the hydrogel, it is expected 
that the hybrid system will delay the release of the components after the application.  
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Figure 2. In vitro gel dissolution profiles of the systems. 
 
The gelation of the system after its inoculation leads to a prolonged release of the components as 
the gel dissolves inside the animal body, which is a key factor to get a better drug distribution in 
tumors [13, 14]. It is known that the drug access to tumor cells is achieved via bloodstream [13, 14]. 
So, if there is no continuous infusion, only drugs that are near the blood vessels can be killed and cells 
that are more distant are able to survive and regenerate the tumor [13, 14]. Oppositely, a continuous 
infusion permits a longer residence time of the drug, ensuring a better distribution so a larger number 
of cells are reached (Fig. 3). 
  
 
Figure 3. Schematic illustration of drug distribution in a) no continuous infusion and b) continuous 
infusion (prolonged-release) 
In vivo macroscopic analyses 
After treatment, macroscopic changes regarding organ conditions were observed in order to get 
preliminary information on the antitumor potential of the systems (Table 2). 
 
 
Table 2.  Observed macroscopic changes of five experimental groups. 
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Macroscopic observation Control Cancer S1 S2 S3 
No apparent macroscopic 
changes 
100% - - - 66,6% 
Lesion in prostate base - 100% 100% 66,6% 33,3% 
Metastasis - 100% 100% 33,3% - 
 
 
It is possible to observe in Table 2 a decrease in frequency of metastasis and prostatic lesions that is 
clearly proportional to MSNs concentration. This calls the attention for the role of the nanoparticles in 
this process, suggesting that the MSNs might be determinant in a possible improvement of tumor 
conditions.   
It is known that nanoparticles are submitted to the enhanced permeability retention (EPR) effect, 
that allow macromolecules and particles up to 100 nm to accumulate in interstitial space of tumor cells 
[15]. This may increase the delivery of SIL, leading to a combined effect from the drug and the 
nanoparticles on tumor cells.  
 
4.  Conclusions 
 
To get preliminary results of the antitumor potential of the association of SIL, MSNs and PF-127, we 
developed three systems that differed only by the MSNs concentration and treated rats with chemically 
induced prostate cancer. Preliminary macroscopic analyses showed an interesting decrease in 
frequency of metastasis and prostatic lesions that was proportional to MSNs concentration. The results 
suggest that the MSNs might be determinant in the treatment. Further studies are necessary to confirm 
the antitumor potential of the systems, but in a first moment, we can associate the results to a 
combined effect from SIL and MSNs, caused by EPR effect along with sustained and prolonged 
release of the drug. This avoids premature degradation of the drug and enables its cell internalization, 
achieving a better drug distribution and increasing its efficacy. Thus, we open a new perspective of 
using MSNs as carriers for SIL in a new platform for prostate cancer treatment, using SIL as the main 
therapy.  
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